SCHEMBL4131194

SCHEMBL4131194

CCOC(=O)C(C(=O)OCC)C(=O)C(C)(Cc1ccc(F)c(Cl)c1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
CNR2 P34972 1/20 0.36
KIF11 P52732 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PTPRC P08575 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPA Q15257 1/20 0.36
LMNA P02545 1/20 0.35
TSHR P16473 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
PTGES O14684 1/20 0.35
CACNA1G O43497 1/20 0.35
MMP8 P22894 1/20 0.34
S1PR3 Q99500 1/20 0.34
PIK3CA P42336 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4131201 0.85 MMP2 (0.36) MMP2MMP3CNR2KIF11TSHR
SCHEMBL4147231 0.82 CNR2 (0.43) MMP2MMP3CNR2KIF11TSHR
SCHEMBL4135204 0.80 CNR2 (0.42) MMP2MMP3CNR2KIF11PTPN1
SCHEMBL1626109 0.77 L3MBTL1 (0.40) CNR2L3MBTL1LMNATSHRSMN1; SMN2
SCHEMBL4000449 0.75 PIN1 (0.43) LMNATSHRSMN1; SMN2MMP8MEN1
SCHEMBL4007055 0.73 KIF11 (0.42) KIF11L3MBTL1LMNATSHRSMN1; SMN2
SCHEMBL1626321 0.72 MAPT (0.40) KIF11LMNASMN1; SMN2MEN1KMT2A
SCHEMBL4007259 0.72 PIN1 (0.42) L3MBTL1LMNATSHRSMN1; SMN2MMP8
SCHEMBL4123392 0.72 MAPT (0.42) L3MBTL1LMNATSHRSMN1; SMN2MMP8
SCHEMBL4127273 0.72 PIN1 (0.42) L3MBTL1LMNATSHRSMN1; SMN2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009032177-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-12 WO disclosed
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II IDENIX PHARMACEUTICALS, INC. (US) 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090060866-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II POLR2E, POLR2H, POLR2A MMP2 677/4885MMP3 3421/4885CNR2 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.